24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:00
Shlomo Kramer-backed Token Security emerges from stealth with $7 million
16:00
XTEND lands $40 million Series B for robot and drone operating system
15:03
Full list of Israeli high-tech funding rounds in 2024
15:00
Panax raises $10 million Series A for AI-powered cash flow management platform
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
2
Unstoppable Wiz: Cyber startup nets another $1 billion in funding as valuation jumps to $12B
3
Akamai acquiring cyber startup Noname Security for $450 million
4
Moritz code: Inside the mind of the best VC investor ever
5
Wiz deal to acquire Lacework collapses
More news
Pharma
20 stories about Pharma
Teva Shares Rise Following FDA Approval of Migraine Drug
16.09.18
|
Dror Reich
Teva’s new migraine drug is forecasted to bring in $500 million in sales annually
Gastro Treatment Company RedHill Jumps on Nasdaq Following Successful Clinical Trial
30.07.18
|
Lilach Baumer
The Tel Aviv-headquartered company stated its Crohn's disease treatment trial met its primary endpoint and key secondary endpoints
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
24.07.18
|
Lilach Baumer
The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market
United Therapeutics to Acquire Pharma Company SteadyMed in a $216 Deal
30.04.18
|
Amarelle Wenkert
In 2017, Israeli-founded SteadyMed won a patent war against United Therapeutics
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
29.04.18
|
Racheli Bindman
Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April
Israeli Cannabis Device Developer Kanabo to Set Up Marijuana Farm in Europe
27.04.18
|
Tofi Stoler
To carry out the plan, Kanabo is partnering with San Francisco-Based Cannabis Extract Manufacturer Constance Therapeutics
Israeli Pharmacies To Begin Selling Medical Marijuana Products
09.04.18
|
Sefi Krupsky
On April 20, selected Israeli pharmacies will begin selling prescription cannabis products as part of a pilot program for the regulation of medical marijuana sales in Israel
Teva Executive Calls Company’s Fourth Quarter “Fairly Good”
11.02.18
|
Dror Reich
Following the publication of the company's reports, S&P Global downgraded Teva’s corporate credit rating to junk bonds
Censa Pharmaceuticals Signs Joint Development Agreement with Biotech Company Retrophin
07.01.18
|
Lilach Baumer
Censa, a company developing treatments for orphan metabolic diseases, is a portfolio company of Israel-based Arkin Bio Ventures
Check Point Founder Invests in Clinical Stage Company Regenera Pharma
02.01.18
|
Dror Reich
The company intends to use the funding for a phase 3 clinical trial of its drug for sudden vision loss
The Year’s Seven Key Trends in Israeli Mergers and Acquisitions
29.12.17
|
Micki Shapira
Even without counting the Mobileye deal, 2017 was another strong year for M&A in Israel
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Employees Protest Outside Teva’s Israeli Facilities
14.12.17
|
Omer Kabir, Yoav Stoler and Keren-Or Grinberg
The demonstrations outside the company's facilities held Thursday foreshadow a full-out strike planned by the company’s employees for Sunday
Teva to Let Go 14,000 Employees Over the Next Two Years
14.12.17
|
Lilach Baumer
The company released a statement detailing its reconstruction plan Thursday. CEO Kåre Schultz elaborated on the plan during a call with investors
Israeli Pharma Company Wavelength Appoints New CEO
30.11.17
|
CTech
Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million
Teva Announces Restructuring, Ousts Second in Command
27.11.17
|
Golan Hazani
The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
With New CEO in Seat, Teva Lowers Outlook
02.11.17
|
Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market
31.10.17
|
Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
Teva Loses Copaxone Market Exclusivity
04.10.17
|
Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
Previous Articles
More Articles
Please ensure Javascript is enabled for purposes of
website accessibility
